Global M&A Volume Hits Record $2.6 Trillion in First Half
N.R. Finch
Global M&A volume reached a record $2.6 trillion in the first half of 2026, up 58% year-on-year, yet deal count barely budged — money is piling into mega-deals, and whether it spreads to small- and mid-caps in H2 will test this cycle's breadth.
What does $2.6 trillion actually look like?
First-half global M&A totaled $2.6 trillion, up 58% year-on-year — the highest on record for any first half.
Deal count stayed roughly flat. This means → individual deal sizes ballooned, with capital concentrating in mega-transactions.
In plain terms = the M&A market isn't blooming broadly — it's giants swallowing giants.
Who is writing the biggest checks?
The single largest deal: the now-public SpaceX agreed to acquire Elon Musk's AI company xAI for $250 billion, the defining transaction of this cycle.
SpaceX is simultaneously pursuing a $60 billion acquisition of Anysphere, the parent of AI coding tool Cursor — one buyer powering two mega-deals.
Other heavyweights: NextEra Energy acquiring Dominion Energy for nearly $120 billion; Equity Residential and AvalonBay Communities merging; and People Inc. proposing to buy casino operator MGM Resorts — the latter two each valued above $35 billion.
Do mega-deals help smaller stocks?
Mega-M&A directly supports takeover premiums for large-caps, but the lift to small- and mid-cap stocks is typically limited.
Yet the Russell 2000 is up over 20% year-to-date, outpacing the S&P 500, the Dow, and the Nasdaq; the S&P MidCap 400 has gained 15%. This reflects improving earnings expectations for smaller companies, underpinned by U.S. economic resilience.
D.A. Davidson co-CIO James Ragan told *Barron's*: "Capital markets are open and money can be put to work — that's a positive signal." He added that the current environment favors more mid- and small-cap deal-making.
Which sectors are next in line?
Biotech is the top watch-list. Large pharma companies are actively hunting early-stage biotech firms to replenish their drug pipelines — the portfolio of new drugs under development.
Software and services are also in play. Jefferies analysts argue that AI-driven valuation pressure on some firms has lowered the price bar for buyers. This means → acquirers can move at cheaper multiples, fueling deal appetite.
Accenture has already raised its 2026 M&A budget from $5 billion to $9 billion — nearly doubling it, voting for the trend with its checkbook.
What to watch in the second half?
Whether the M&A wave spreads from mega-deals to small- and mid-cap targets is the key test of this cycle's breadth.
Freedom Capital Markets chief strategist Jay Woods noted: "Industry trends are favorable and M&A activity is heating up."
In plain terms = the first half proved that money is willing to move; the second half will show whether it's willing to move toward smaller targets.
Content is for reference only, not financial advice.